Author Correction: Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth

Affiliations

¹ Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
² Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
³ Program in Molecular Pharmacology, Department of Medicine, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY, USA.
⁴ Department of Chemistry, Revolution Medicines, Inc., Redwood City, CA, USA.
⁵ Department of Discovery Technologies, Revolution Medicines, Inc., Redwood City, CA, USA.
⁶ Gerald Bronfman Department of Oncology and Departments of Biochemistry and Experimental Medicine, Lady Davis Institute, McGill University, Montréal, QC, Canada.
⁷ Département de Médecine, Département de Biochimie et Médecine Moléculaire, Université de Montréal, Montréal, QC, Canada.
⁸ Maisonneuve-Rosemont Hospital Research Centre, Montréal, QC, Canada.
⁹ Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden.
¹⁰ Department of Non-clinical Development and Clinical Pharmacology, Revolution Medicines, Inc., Redwood City, CA, USA.
¹¹ Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA. jan@revmed.com.
¹² Program in Molecular Pharmacology, Department of Medicine, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY, USA. rosenn@mskcc.org.

^# Contributed equally.

Published Erratum

Bianca J Lee et al. Nat Chem Biol. 2021 Nov.

. 2021 Nov;17(11):1209.

doi: 10.1038/s41589-021-00905-4.

¹ Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
² Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
³ Program in Molecular Pharmacology, Department of Medicine, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY, USA.
⁴ Department of Chemistry, Revolution Medicines, Inc., Redwood City, CA, USA.
⁵ Department of Discovery Technologies, Revolution Medicines, Inc., Redwood City, CA, USA.
⁶ Gerald Bronfman Department of Oncology and Departments of Biochemistry and Experimental Medicine, Lady Davis Institute, McGill University, Montréal, QC, Canada.
⁷ Département de Médecine, Département de Biochimie et Médecine Moléculaire, Université de Montréal, Montréal, QC, Canada.
⁸ Maisonneuve-Rosemont Hospital Research Centre, Montréal, QC, Canada.
⁹ Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden.
¹⁰ Department of Non-clinical Development and Clinical Pharmacology, Revolution Medicines, Inc., Redwood City, CA, USA.
¹¹ Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA. jan@revmed.com.
¹² Program in Molecular Pharmacology, Department of Medicine, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY, USA. rosenn@mskcc.org.

^# Contributed equally.

No abstract available

Erratum for

Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth.
Lee BJ, Boyer JA, Burnett GL, Thottumkara AP, Tibrewal N, Wilson SL, Hsieh T, Marquez A, Lorenzana EG, Evans JW, Hulea L, Kiss G, Liu H, Lee D, Larsson O, McLaughlan S, Topisirovic I, Wang Z, Wang Z, Zhao Y, Wildes D, Aggen JB, Singh M, Gill AL, Smith JAM, Rosen N. Lee BJ, et al. Nat Chem Biol. 2021 Oct;17(10):1065-1074. doi: 10.1038/s41589-021-00813-7. Epub 2021 Jun 24. Nat Chem Biol. 2021. PMID: 34168367 Free PMC article.